

Steroid induced osteopaenia: prophylaxis and treatment in paediatric rheumatic diseases

Submission date 22/08/2005	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 15/09/2005	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 24/05/2016	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Madeleine Rooney

Contact details
Dept of Rheumatology
Queen's University of Belfast
Musculoskeletal Education & Research Unit
Musgrave Park Hospital
Stockman's Lane
Belfast
United Kingdom
BT9 7JB
+44 (0)2890902820
m.rooney@qub.ac.uk

Additional identifiers

Protocol serial number
15936

Study information

Scientific Title

Steroid induced osteopaenia: prophylaxis and treatment in paediatric rheumatic diseases

Study objectives

That the bisphosphonate Risedronate will significantly reduce steroid induced osteopaenia in children and adolescents

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Prevention

Health condition(s) or problem(s) studied

Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Juvenile Systemic Lupus Erythematosus (JSLE)

Interventions

Randomised to receive either one alpha hydroxycholecalciferol (one-alpha) Or risedronate

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

One alpha hydroxycholecalciferol, Risedronate

Primary outcome(s)

An improvement of 0.5 SDS in bone mineral density (BMD) in the treated group compared to the control

Key secondary outcome(s))

No secondary outcome measures

Completion date

30/06/2009

Eligibility

Key inclusion criteria

Children and adolescents with JIA, JSLE, JDM, commencing steroids or currently treated with steroids between the ages of 4 and 18 years

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Child

Lower age limit

4 years

Upper age limit

18 years

Sex

All

Key exclusion criteria

1. Children who are commencing steroids but where the duration of steroid treatment is expected to be less than 3 months (i.e. short term) should not be recruited
2. Children receiving intermittent pulses of intravenous steroids
3. Co-morbid conditions known to be associated with osteopaenia: Cystic fibrosis, malabsorption, severe renal disease, severe asthma, cancer, osteogenesis imperfecta, inflammatory bowel disease
4. Have a history of using any bisphosphonate (except for more than a single dose of risedronate) and/or fluoride (>10 mg per day)
5. Have a history of cancer
6. Have untreated rickets within one year prior to enrolment
7. Evidence of clinically significant organic or psychiatric disease on history or physical examination which in the opinion of the investigator would prevent the patient from completing the study
8. Have markedly abnormal pretreatment laboratory findings, except if in the opinion of the investigator, it would not prevent the patient from completing the study
9. Have a history of using anabolic steroids/estrogens/androgens within one year of enrolment
10. Have a documented history of an abnormal or allergic reaction to bisphosphonates
11. Pregnancy or sexually active subjects unwilling to take appropriate contraceptive measures
12. Any limb-lengthening procedure within 6 months of enrolment
13. Participation in another clinical trial, involving active intervention within 30 days prior to enrolment
14. Creatinine clearance <100 ml/min

Date of first enrolment

01/01/2006

Date of final enrolment

30/06/2009

Locations

Countries of recruitment

United Kingdom

Northern Ireland

Study participating centre

Dept of Rheumatology

Belfast

United Kingdom

BT9 7JB

Sponsor information

Organisation

Greenpark Healthcare Trust (UK)

ROR

<https://ror.org/02tdmfk69>

Funder(s)

Funder type

Charity

Funder Name

Arthritis Research Campaign (ARC) (UK) (ref:15936)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration